⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Zepbound (Tirzepatide) | Accelerate Your Fibrosis Research

Home/Drugs/Zepbound

Zepbound

Tirzepatide

Phase 3

Sponsor: Eli Lilly

Indication: MASH / Obesity

Mechanism of Action

GLP-1/GIP Dual Agonist

Target: GLP-1Target: GIP

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT07096063

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Org:Brigham and Women's Hospital

NOT_YET_RECRUITING

Relevant Publications (PubMed)

Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.

Saeed ZI, Apovian CM

Curr Atheroscler Rep2025 Dec 18

Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.

Hossain A, Fahim M, Abdalla M et al.

Cureus2025 Nov

Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.

Marinho TS, Bittencourt JOA, Aguila MB et al.

Brain Res2025 Dec 15

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

Validated Models

This drug has been validated in the following preclinical models:

NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

Phase:PHASE2, PHASE3Org:McGill University Health Centre/Research Institute of the McGill University Health Centre

COMPLETEDNCT04657016

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT05822544

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

Phase:PHASE1Org:OrsoBio, Inc

ACTIVE_NOT_RECRUITINGNCT06603571

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Phase:PHASE2Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov

Nicholls SJ, Pavo I, Bhatt DL et al.

N Engl J Med2025 Dec 18

Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide.

Banji D, Alshahrani S, Alfarhan M et al.

Saudi Pharm J2025 Dec 17

View more on PubMed